From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 18, 2025

The integration of fecal microbiota transplantation (FMT) with immune checkpoint inhibitors (ICIs) presents a promising approach for enhancing cancer treatment efficacy and overcoming therapeutic resistance. This review critically examines the controversial effects FMT on ICIs outcomes elucidates underlying mechanisms. We investigate how modulates gut composition, microbial metabolite profiles, tumor microenvironment, thereby influencing effectiveness. Key factors efficacy, including donor selection criteria, recipient characteristics, administration protocols, are comprehensively discussed. delineates strategies optimizing formulations systematically monitoring post-transplant microbiome dynamics. Through comprehensive synthesis evidence from clinical trials preclinical studies, we elucidate potential benefits challenges combining across diverse types. While some studies report improved outcomes, others indicate no benefit or adverse effects, emphasizing complexity host-microbiome interactions in immunotherapy. outline critical research directions, encompassing need large-scale, multi-center randomized controlled trials, in-depth ecology multi-omics approaches artificial intelligence. Regulatory ethical addressed, underscoring imperative standardized protocols rigorous long-term safety assessments. seeks to guide future endeavors applications FMT-ICIs combination therapy, improve patient while ensuring both efficacy. As this rapidly evolving field advances, maintaining judicious balance between openness innovation cautious scrutiny is crucial realizing full modulation

Language: Английский

---

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 422 - 422

Published: Feb. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Language: Английский

---

Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: 208, P. 104629 - 104629

Published: Jan. 27, 2025

Language: Английский

---

Tumor microbiome: roles in tumor initiation, progression, and therapy

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: Feb. 8, 2025

Abstract Over the past few years, tumor microbiome is increasingly recognized for its multifaceted involvement in cancer initiation, progression, and metastasis. With application of 16S ribosomal ribonucleic acid (16S rRNA) sequencing, intratumoral microbiome, also referred to as tumor-intrinsic or tumor-resident has been found play a significant role microenvironment (TME). Understanding their complex functions critical identifying new therapeutic avenues improving treatment outcomes. This review first summarizes origins composition these microbial communities, emphasizing adapted diversity across diverse range types stages. Moreover, we outline general mechanisms by which specific microbes induce including activation carcinogenic pathways, deoxyribonucleic (DNA) damage, epigenetic modifications, chronic inflammation. We further propose may evade immunity promote angiogenesis support while uncovering influences on each step metastatic cascade, such invasion, circulation, seeding secondary sites. Additionally, closely associated with drug resistance efficacy modulating immune responses, metabolism, apoptotic pathways. Furthermore, explore innovative microbe-based strategies, engineered bacteria, oncolytic virotherapy, other modalities aimed at enhancing immunotherapeutic efficacy, paving way microbiome-centered frameworks.

Language: Английский

---

Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 813 - 813

Published: Feb. 26, 2025

The emergence of cancer immunotherapy has revolutionized treatment, offering remarkable outcomes for patients across various malignancies. However, the heterogeneous response to underscores necessity understanding additional factors influencing treatment efficacy. Among these factors, human microbiota garnered significant attention its potential role in modulating immune response. Body: This review explores intricate relationship between and immunotherapy, highlighting recent advances mechanisms underlying microbial influence on outcomes. Insights into microbiome's impact not only deepen our pathogenesis but also hold promise personalized therapeutic strategies aimed at optimizing patient

Language: Английский

---

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(3), P. e010928 - e010928

Published: March 1, 2025

Immunotherapy of cancer is now an essential pillar treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration new strategies incorporating agents in clinical practice. Immunotherapies perturb complex system interactions among genomically unstable cells, diverse cells within the microenvironment including systemic adaptive innate cells. The drive to develop increasingly effective immunotherapy regimens tempered by risk immune-related adverse events. Evidence-based biomarkers that measure potential therapeutic response and/or toxicity critical guide optimal patient care contextualize results trials. Responding lack guidance on biomarker testing early-phase trials, we propose definition listing recommended inclusion all such protocols. These recommendations based consensus provided Society Cancer (SITC) Clinical Immuno-Oncology Network (SCION) faculty input from SITC Pathology Biomarker Committees Journal ImmunoTherapy readership. A consensus-based selection was conducted using Delphi survey SCION faculty. Regular updates these planned. inaugural list includes complete blood count differential generate neutrophil-to-lymphocyte ratio or immune-inflammation index, serum lactate dehydrogenase albumin, programmed death-ligand 1 immunohistochemistry, microsatellite stability assessment, mutational burden. Inclusion across trials will capture variation provide deeper insight into novel established therapies, support improved stratification later-phase

Language: Английский

---

Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2040 - 2040

Published: March 17, 2025

Oncologists increasingly recognize the microbiome as an important facilitator of health well a contributor to disease, including, specifically, cancer. Our knowledge etiologies, mechanisms, and modulation states that ameliorate or promote cancer continues evolve. The progressive refinement adoption “omic” technologies (genomics, transcriptomics, proteomics, metabolomics) utilization advanced computational methods accelerate this evolution. academic center network, with its immediate access extensive, multidisciplinary expertise scientific resources, has potential catalyze research. Here, we review our current understanding role gut in prevention, predisposition, response therapy. We underscore promise operationalizing network uncover structure function microbiome; highlight unique microbiome-related expert resources available at City Hope Comprehensive Cancer Center example team science achieve novel clinical discovery.

Language: Английский

---

Fighting Antibiotic Resistance: Insights Into Human Barriers and New Opportunities

BioEssays, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

The public health issue of bacterial multi-resistance to antibiotics has gained awareness among the public, researchers, and pharmaceutical sector. Nevertheless, spread antimicrobial resistance been considerably aggravated by human activities, climate change, subsequent increased release antibiotics, drug-resistant bacteria, antibiotic genes in environment. extensive use for medical veterinary purposes not only induced increasing but also other problems, including negative effects on patient's microbiome. Preventive strategies, new treatment modalities, surveillance are progressively set up. A comprehensive approach is, however, lacking urgently tackling this adverse situation. To address challenge, we discussed here main causes driving pollution environment factors favorable emergence drug resistance. We next propose some key priorities research, prevention, surveillance, education supervise an effective clinical sustainable response.

Language: Английский

---

Different Levels of Therapeutic Strategies to Recover the Microbiome to Prevent/Delay Acute Lymphoblastic Leukemia (ALL) or Arrest Its Progression in Children

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3928 - 3928

Published: March 31, 2024

Changes in the components, variety, metabolism, and products of microbiomes, particularly gut microbiome (GM), have been revealed to be closely associated with onset progression numerous human illnesses, including hematological neoplasms. Among latter pathologies, there is acute lymphoblastic leukemia (ALL), most widespread malignant neoplasm pediatric subjects. Accordingly, ALL cases present a typical dysfunctional GM during all its clinical stages resulting inflammation, which contributes progression, altered response therapy, possible relapses. Children characteristic variations composition, functions, such alterations may influence predict complications prognosis after chemotherapy treatment or stem cell hematopoietic transplants. In addition, growing evidence also reports ability formation, growth, roles newborn's system through process developmental programming fetal life as well susceptibility onco-hematological namely ALL. Here, we suggest some therapeutic strategies that can applied at two levels intervention recover consequently prevent/delay arrest progression.

Language: Английский

---

Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8+ T cell infiltration

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 24, 2024

Immune checkpoint inhibitors (ICIs) have emerged as a novel and effective treatment strategy, yet their effectiveness is limited to subset of patients. The gut microbiota, recognized promising anticancer adjuvant, being increasingly suggested augment the efficacy ICIs. Despite this, causal link between microbiota success immunotherapy not well understood. This gap in knowledge has driven us identify beneficial explore underlying molecular mechanisms.

Language: Английский

---